Abstract
Annual Review of Pharmacology and Toxicology
Vol. 47:
565-592
(Volume publication date February 2007)
(doi:10.1146/annurev.pharmtox.47.120505.105256)
First published online as a Review in Advance on September 26, 2006The Obesity Epidemic: Current and Future Pharmacological Treatments Karl G. Hofbauer,1 Janet R. Nicholson,1 and Olivier Boss21Applied Pharmacology, Biozentrum/Pharmazentrum, University of Basel, CH 4056 Basel, Switzerland; email: karl.hofbauer@unibas.ch 2Sirtris Pharmaceuticals Inc., Cambridge, Massachusetts 02139 Abstract The unabated rise in the prevalence of obesity is a challenge for global health care systems. Efforts to reverse this trend by dietary or behavioral counseling have not been successful, which has stimulated efforts to find a role for pharmacotherapy. Currently only a small number of antiobesity drugs are approved for long-term use and only a few compounds are in clinical development. Despite recent progress in the understanding of the regulation of energy balance, drug discovery has been less productive than expected. In the present review, the clinically available antiobesity agents are discussed. Examples of drug candidates that are currently in development are given and the possible future range of antiobesity agents is illustrated by the targets being addressed in drug discovery. Finally, the efficacy of antiobesity agents and their value in the treatment of obesity are assessed in comparison with other therapeutic approaches, such as surgery and changes in lifestyle. Acronyms and Definitions Body mass index (BMI): the quotient of body weight in kilograms divided by body height in meters squared (BMI = kg/m2). It correlates with the amount of body fat Metabolic syndrome: a cluster of metabolic and cardiovascular risk factors. Insulin resistance is considered to be one of the underlying causes, but a common pathogenetic factor has not yet been identified. Overweight and obese: a BMI range between 25 and 29.9 kg/m2 is defined as overweight; a BMI above 30 kg/m2 is obese. At the BMI cut-off point of 30 kg/m2 the risk of obesity-associated diseases starts to increase exponentially Prevalence: percentage of a population that is affected by a certain disease at a given point in time Most recent citing papers (via CrossRef)Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant International Journal of Obesity 32(9):1363-1372 (2008) Public awareness of the abuse of herbs and drugs to decrease body weight: a novel national survey in Jordan Journal of Public Health 16(3):205-213 (2008) Oral administration of the antiobesity drugs, sibutramine and rimonabant, increases acetylcholine efflux selectively in the medial prefrontal cortex of the rat Molecular Psychiatry 13(3):240-241 (2008) Cytometric Analysis of the Cytotoxic Action of Adenosine 5'-Monophosphate on Rat Thymocytes JOURNAL OF HEALTH SCIENCE 54(6):692-696 (2008) The obesity pandemic Therapy 4(5):497-500 (2007)
|
|
|
Users who read this review also read:
| Francis Levi, Ueli Schibler Annual Review of Pharmacology and Toxicology. Volume 47, Page 593-628, Feb 2007 Abstract
| Full Text
| PDF (476 KB)
|
Add to Favorites
| Related | |
| Rima Kaddurah-Daouk, Bruce S. Kristal, Richard M. Weinshilboum Annual Review of Pharmacology and Toxicology. Volume 48, Page 653-683, Feb 2008 Abstract
| Full Text
| PDF (698 KB)
|
Add to Favorites
| Related | |
| Antonella Viola, Andrew D. Luster Annual Review of Pharmacology and Toxicology. Volume 48, Page 171-197, Feb 2008 Abstract
| Full Text
| PDF (1037 KB)
|
Add to Favorites
| Related | |
| A.G. de Boer, P.J. Gaillard Annual Review of Pharmacology and Toxicology. Volume 47, Page 323-355, Feb 2007 Abstract
| Full Text
| PDF (295 KB)
|
Add to Favorites
| Related | |
|
|